Bringing a novel therapeutic to market is a complex and costly journey, and toxicity remains a leading reason for failure along the way. Despite remarkable advances ...

Mammalian cell line development is essential to biologics manufacturing, ensuring stable, high-yield expression of therapeutic proteins. With expanding biologics pip...

Increased demand for higher product yield in biologics requires optimal use of existing manufacturing capacity. Process intensification is one way a facility can mee...

This article presents a quality comparison between the recombinant origin Semaglutide drug substance made by Aurisco and the innovator’s injectable and oral Semaglut...

Executive Summary  The entry of the 5,000L single-use bioreactor (SUB) into biologics manufacturing is providing an important bridge between small-scale and ...

Bioluminescence resonance energy transfer (BRET) is a technology often used to probe the proximity of molecules within live cells. BRET assays have many applications...

As industry leaders and customers from across the globe gathered to discuss the latest trends and challenges in drug development and manufacturing at this year’s BIO...

Early-phase drug product development and manufacturing are crucial steps in transforming promising drug candidates into viable, life-changing therapies. In the fast-...

Advances in CAR-T cell therapy have carved a path for improved treatments in the field of oncology, in particular haematological cancers. In 2018, the European Medic...